Dissociable hindbrain GLP1R circuits for satiety and aversion.

Autor: Huang KP; Monell Chemical Senses Center, Philadelphia, PA, USA., Acosta AA; Monell Chemical Senses Center, Philadelphia, PA, USA., Ghidewon MY; Monell Chemical Senses Center, Philadelphia, PA, USA.; Department of Neuroscience, University of Pennsylvania, Philadelphia, PA, USA., McKnight AD; Monell Chemical Senses Center, Philadelphia, PA, USA.; Department of Neuroscience, University of Pennsylvania, Philadelphia, PA, USA., Almeida MS; Monell Chemical Senses Center, Philadelphia, PA, USA., Nyema NT; Monell Chemical Senses Center, Philadelphia, PA, USA., Hanchak ND; Monell Chemical Senses Center, Philadelphia, PA, USA., Patel N; Monell Chemical Senses Center, Philadelphia, PA, USA., Gbenou YSK; Monell Chemical Senses Center, Philadelphia, PA, USA., Adriaenssens AE; Department of Neuroscience, Physiology, and Pharmacology, University College London, London, UK., Bolding KA; Monell Chemical Senses Center, Philadelphia, PA, USA.; Department of Neuroscience, University of Pennsylvania, Philadelphia, PA, USA., Alhadeff AL; Monell Chemical Senses Center, Philadelphia, PA, USA. aalhadeff@monell.org.; Department of Neuroscience, University of Pennsylvania, Philadelphia, PA, USA. aalhadeff@monell.org.

Publikováno v: Nature [Nature] 2024 Aug; Vol. 632 (8025), pp. 585-593. Date of Electronic Publication: 2024 Jul 10.

GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders.

Autor: Samms RJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN samms_ricardo_j@lilly.com aea35@medschl.cam.ac.uk., Sloop KW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN., Gribble FM; Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K., Reimann F; Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K., Adriaenssens AE; Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K. samms_ricardo_j@lilly.com aea35@medschl.cam.ac.uk.

Publikováno v: Diabetes [Diabetes] 2021 Sep; Vol. 70 (9), pp. 1938-1944. Date of Electronic Publication: 2021 Jun 27.

The core clock gene, Bmal1, and its downstream target, the SNARE regulatory protein secretagogin, are necessary for circadian secretion of glucagon-like peptide-1.

Autor: Biancolin AD; Department of Physiology, University of Toronto, Toronto, ON, Canada., Martchenko A; Department of Physiology, University of Toronto, Toronto, ON, Canada., Mitova E; Department of Physiology, University of Toronto, Toronto, ON, Canada., Gurges P; Department of Physiology, University of Toronto, Toronto, ON, Canada., Michalchyshyn E; Department of Physiology, University of Toronto, Toronto, ON, Canada., Chalmers JA; Department of Physiology, University of Toronto, Toronto, ON, Canada., Doria A; Department of Medicine, Harvard Medical School, Boston, MA, USA; Research Division, Joslin Diabetes Center, Boston, MA, USA., Mychaleckyj JC; Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA., Adriaenssens AE; Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK., Reimann F; Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK., Gribble FM; Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK., Gil-Lozano M; Department of Physiology, University of Toronto, Toronto, ON, Canada., Cox BJ; Department of Physiology, University of Toronto, Toronto, ON, Canada; Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada., Brubaker PL; Department of Physiology, University of Toronto, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address: p.brubaker@utoronto.ca.

Publikováno v: Molecular metabolism [Mol Metab] 2020 Jan; Vol. 31, pp. 124-137. Date of Electronic Publication: 2019 Nov 21.

No direct effect of SGLT2 activity on glucagon secretion.

Autor: Kuhre RE; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Panum Institute, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark.; Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Ghiasi SM; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Panum Institute, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark.; Department of Biology, Faculty of Science, University of Copenhagen, Copenhagen, Denmark., Adriaenssens AE; Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, CB2 0QQ, UK., Wewer Albrechtsen NJ; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Panum Institute, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark.; Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark., Andersen DB; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Panum Institute, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark.; Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Aivazidis A; Translational Science, Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden., Chen L; Translational Science, Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden., Mandrup-Poulsen T; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Panum Institute, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark., Ørskov C; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Panum Institute, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark., Gribble FM; Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, CB2 0QQ, UK., Reimann F; Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, CB2 0QQ, UK., Wierup N; Department of Experimental Medical Science, Faculty of Medicine, Lund University Diabetes Centre, Lund, Sweden., Tyrberg B; Translational Science, Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden., Holst JJ; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Panum Institute, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark. jjholst@sund.ku.dk.; Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. jjholst@sund.ku.dk.

Publikováno v: Diabetologia [Diabetologia] 2019 Jun; Vol. 62 (6), pp. 1011-1023. Date of Electronic Publication: 2019 Mar 22.

Inhibition of the malate-aspartate shuttle in mouse pancreatic islets abolishes glucagon secretion without affecting insulin secretion.

Autor: Stamenkovic JA; Unit of Molecular Metabolism, Department of Clinical Sciences in Malmö, Lund University Diabetes Centre, CRC, Lund University, Skåne University Hospital, Malmö 205 02, Sweden., Andersson LE; Unit of Molecular Metabolism, Department of Clinical Sciences in Malmö, Lund University Diabetes Centre, CRC, Lund University, Skåne University Hospital, Malmö 205 02, Sweden., Adriaenssens AE; †MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Sciences, Addenbrooke's Hospital, Cambridge CB2 0XY, U.K., Bagge A; Unit of Molecular Metabolism, Department of Clinical Sciences in Malmö, Lund University Diabetes Centre, CRC, Lund University, Skåne University Hospital, Malmö 205 02, Sweden., Sharoyko VV; Unit of Molecular Metabolism, Department of Clinical Sciences in Malmö, Lund University Diabetes Centre, CRC, Lund University, Skåne University Hospital, Malmö 205 02, Sweden., Gribble F; †MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Sciences, Addenbrooke's Hospital, Cambridge CB2 0XY, U.K., Reimann F; †MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Sciences, Addenbrooke's Hospital, Cambridge CB2 0XY, U.K., Wollheim CB; ‡Department of Clinical Sciences in Malmö, Lund University Diabetes Centre, CRC, Lund University, Skåne University Hospital, Malmö 205 02, Sweden., Mulder H; Unit of Molecular Metabolism, Department of Clinical Sciences in Malmö, Lund University Diabetes Centre, CRC, Lund University, Skåne University Hospital, Malmö 205 02, Sweden., Spégel P; Unit of Molecular Metabolism, Department of Clinical Sciences in Malmö, Lund University Diabetes Centre, CRC, Lund University, Skåne University Hospital, Malmö 205 02, Sweden.

Publikováno v: The Biochemical journal [Biochem J] 2015 May 15; Vol. 468 (1), pp. 49-63.